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Plasmodium falciparum has the capacity to escape the actions of essentially all antimalarial drugs. ATP-binding cassette (ABC)
transporter proteins are known to cause multidrug resistance in a large range of organisms, including the Apicomplexa parasites.
P. falciparum genome analysis has revealed two genes coding for the multidrug resistance protein (MRP) type of ABC transport-
ers: Pfmrp1, previously associated with decreased parasite drug susceptibility, and the poorly studied Pfmrp2. The role of Pfmrp2
polymorphisms in modulating sensitivity to antimalarial drugs has not been established. We herein report a comprehensive ac-
count of the Pfmrp2 genetic variability in 46 isolates from Thailand. A notably high frequency of 2.8 single nucleotide polymor-
phisms (SNPs)/kb was identified for this gene, including some novel SNPs. Additionally, we found that Pfmrp2 harbors a signifi-
cant number of microindels, some previously not reported. We also investigated the potential association of the identified
Pfmrp2 polymorphisms with altered in vitro susceptibility to several antimalarials used in artemisinin-based combination ther-
apy and with parasite clearance time. Association analysis suggested Pfmrp2 polymorphisms modulate the parasite’s in vitro
response to quinoline antimalarials, including chloroquine, piperaquine, and mefloquine, and association with in vivo parasite
clearance. In conclusion, our study reveals that the Pfmrp2 gene is the most diverse ABC transporter known in P. falciparum
with a potential role in antimalarial drug resistance.
Plasmodium falciparum, the lethal pathogen of human malaria,is notorious for its capacity to develop resistance to chemo-
therapy. From the first observations involving quinine (1) to the
latest reports on emerging artemisinin (ART) resistance (2–4), the
parasite has shown a resilient ability to evade the action of essen-
tially every launched antimalarial drug, independently of the
chemical structure involved. Such an evasive capacity raises the
hypothesis that the parasite is presently developing broad-range
resistance phenotypes, possibly akin to the extensive drug resis-
tance witnessed in other infectious diseases, namely, tuberculosis
(5). This is a legitimate concern, particularly because of the recent
reports of decreased ART sensitivity of the parasite in Southeast
Asia.
Conventional in vitro drug response and the parasite clearance
rate (2, 3) are the main measurements to assess the resistance
phenotype of the parasite, but these procedures involve de-
manding and time-consuming protocols. A practical alterna-
tive is the use of molecular sentinel tools, i.e., molecular mark-
ers based on genetic variations with a valuable predictive
capacity in the identification of the resistance status of the an-
alyzed infection. The development of such tools is dependent
on the understanding of the drug resistance mechanisms and
their associations with variants of particular genes. Such infor-
mation can also provide key clues for the development of new
evidence-based resistance-refractory antimalarials. Moreover,
this type of information is of particular relevance at a moment
when technology for point-of-care genetic analysis is starting
to emerge, allowing a first glimpse of the possibility of person-
alized medicine in the future (6).
Transporter proteins belonging to the ATP-binding cassette
(ABC) superfamily arewell known to be involved in drug efflux, as
they are associated with resistance in a large variety of phyloge-
netically different biological systems (7). These proteins are able to
transport substrates across cell membranes against a concentra-
tion gradient, an action driven by ATP hydrolysis. In particular,
the multidrug resistance-associated protein (MRP)-like subclass
of ABC transporters is well known for transport of drugs out of
cells, contributing to resistance as well as to the redoxmetabolism
pathway (8). Since the antimalarial chloroquine (CQ), and poten-
tially mefloquine (MQ), was reported to be transported by the
humanMRP1 andMRP4 proteins, it has been speculated that the
putativeP. falciparumMRP could have the same capacity and thus
contribute to drug resistance (9, 10). Indeed, P. falciparum is pres-
Received 13 May 2014 Returned for modification 29 June 2014
Accepted 22 September 2014
Published ahead of print 29 September 2014
Address correspondence to Maria Isabel Veiga, mariaveiga@ecsaude.uminho.pt.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/AAC.03337-14.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.03337-14
7390 aac.asm.org Antimicrobial Agents and Chemotherapy p. 7390–7397 December 2014 Volume 58 Number 12
 o
n
 January 14, 2015 by Edward G
. M
iner Library, UNIV O
F RO
CHESTER
http://aac.asm
.org/
D
ow
nloaded from
 
ently known to contain in its genome two genes coding for MRP-
like proteins, namely,Pfmrp1 (11) andPfmrp2 (12). Both PfMRP1
(PlasmoDB gene ID PF3D7_0112200) and PfMRP2 (PlasmoDB
gene ID PF3D7_1229100) proteins are localized in the cytoplas-
micmembrane of the parasite in the asexual stages (13). Addition-
ally, it was observed that the loss of PfMRP1 drug transport capa-
bility resulted in an increased accumulation of antimalarials that
was paralleled by an enhanced in vitro susceptibility to several
antimalarial drugs, including CQ, quinine, and ART (14). A num-
ber of studies on Pfmrp1 diversity have associated single nucleo-
tide polymorphisms (SNPs) in this gene to the parasite in vivo
drug responses, manifested by the selection of specific SNPs upon
treatment (15–17).
In contrast, our knowledge on Pfmrp2 is limited, and its biodi-
versity and possible involvement in antimalarial drug resistance
are still to be disclosed. The localization of PfMRP2 in the plasma
membrane suggests that this ABC transporter may be of relevance
in the efflux of xenobiotics from the parasite cytoplasm, as previ-
ously reported for the structurally related PfMRP1 (14). Also, we
recently showed that upon MQ exposure in vitro, different levels
of Pfmrp2 transcription induction were observed between sensi-
tive and less susceptible strains (18). Additionally, Pfmrp1 and
Pfmrp2 genes have essentially opposite transcriptional patterns
throughout the P. falciparum asexual intraerythrocytic cell cycle,
so that each protein is expressed during different morphological
stages (18, 19). This pattern further suggests a potential functional
complementation between the two proteins that might be of rel-
evance in complex phenotypes of the cell cycle stage-specific drug
response. Lastly, recent microarray-based approaches have iden-
tified a P. falciparum 3D7 subvariant which carries a ca. 4-kb de-
letion at the Pfmrp2 5= putative promoter that is associated with
decreased susceptibility to CQ and MQ (20).
We focused here on the study ofPfmrp2 complete open reading
frame (ORF) sequence diversity in a set of adapted parasites from
an ART resistance focus at the Thai-Burma border, disclosing a
previously unknown natural variation of this gene. Taking advan-
tage of available data on in vitro antimalarial 50% inhibitory con-
centrations (IC50s) and parasite clearance times (PCTs) for this set
of samples (21, 22), we explored the possible association of the
polymorphisms found with modulation of drug sensitivity.
MATERIALS AND METHODS
P. falciparum field isolates. Forty-six culture-adapted P. falciparum field
isolates, originally adapted at Karolinska Institutet (21), were enrolled in
this study. All were isolated from clinical cases of uncomplicated malaria
diagnosed and managed at the Shoklo Malaria Unit in the Mae Sot Dis-
trict, Tak Province, Thailand, where parasite clearance time data were
collected. The chosen parasite set of infections represented a relatively
homogeneous and specific population, in line with the objectives of ob-
taining a better understanding of the specific influence of the Pfmrp2
variation in drug responses.
The study was ethically cleared by the relevant institutions, and the
blood samples were obtained upon informed consent provided in the
local language (21).
Pfmrp2 molecular analysis. The Pfmrp2 gene (6,327 bp on the 3D7
laboratory strain) was PCR amplified from genomicDNA, extracted from
culture-adapted Thai strains (21) in 8 fragments, in order to cover the
entire ORF. Amplification and sequencing primers are described in Table
S1 in the supplemental material. The PCR amplifications were performed
in a total volume of 50 l with 0.2 M each forward and reverse primer,
0.2 mM deoxynucleoside triphosphates, 2.5 mM MgCl2, and 2 U GoTaq
DNA polymerase (Promega Biotech AB). The thermal cycle program was
performed with a starting DNA denaturation temperature of 94°C for 2
min, followed by three touchdown cycles: 10 cycles of 93°C for 15 s, 57°C
for 30 s, and 72°C for 90 s; 25 cycles of 93°C for 15 s, 55°C for 30 s, and 72°C
for 90 s; followed by 10 cycles of 93°C for 15 s, 53°C for 30 s, and 72°C for
90 s. Fragments that did not amplify were subjected to a nested amplifi-
cationwith the primers described inTable S1 in the supplementalmaterial
and the same thermal cycle program. The resulting PCR products were
confirmed through agarose gel electrophoresis for specificity and a low
presence of unspecific amplification. The direct sequencing of the ampli-
cons was outsourced to Macrogen Inc. (Seoul, South Korea).
Analysis of the sequence chromatograms. Due to the complexity of
the gene, sequence chromatogram files were analyzed by using two bioin-
formatic approaches. Sequence chromatogramfiles were analyzed by base
calls using phred version 0.020425.c (23) and aligned to the P. falciparum
3D7 genome reference sequence (PlasmoDB gene IDPF3D7_1229100) by
using the alignment program ssaha2 version 2.5.1 (24). The program was
configured to report only the best alignment for each match. A custom
Perl script was used to call single nucleotide polymorphisms and poly-
morphic microindels (MIs) from the alignments. A position was called
polymorphic if either the position had more than one read to support the
nucleotide difference or the quality score of the position was 20 or higher.
The Tablet program was used to visualize alignments (25). The other
approach to analyze the sequence chromatogramfiles was with the Staden
package (26). To identify sequence polymorphisms, the consensus se-
quence for each strain was compared with the corresponding gene se-
quence of the Plasmodium falciparum 3D7 genome reference sequence by
using MUSCLE (27) and manually inspected for alignment errors.
In addition to the 3D7 genome reference sequence, five other reference
and published parasite lines sequences were downloaded: Dd2 (http:
//www.ncbi.nlm.nih.gov/nuccore/AASM00000000), Hb3 (http://www
.ncbi.nlm.nih.gov/nuccore/AANS00000000), UGT5.1 (http://www.ncbi
.nlm.nih.gov/nuccore/AMYP00000000), RAJ116 (http://www.ncbi.nlm
.nih.gov/nuccore/ACBR00000000), and IGH-CR14 (http://www.ncbi
.nlm.nih.gov/nuccore/ACBS00000000). The Pfmrp2 gene sequence was
extracted and used in the alignments for sequence comparisons with our
set of samples.
Determined antimalarial in vitro 50% inhibitory concentrations
and parasite clearance times. The 46 Thai isolates were previously phe-
notyped for the in vitro IC50s of ART, dihydroartemisinin (DHA), MQ,
lumefantrine (LUM), piperaquine (PPQ), and CQ. Briefly, the IC50s were
determined by culturing the parasite (synchronized at ring stage with
0.05% parasitemia and 1.5% hematocrit) in the presence of serial dilu-
tions of the aforementioned antimalarial drugs. After 72 h of incubation at
37°C under restricted O2 conditions, the cells were lysed and analyzed by
the histidine-rich protein 2-based double-site sandwich enzyme-linked
immunosorbent assay (28). Further detailed information can be found in
the original reports (21, 22).
In this set of Thai isolates, the patient parasite clearance times ranged
from 6 to 132 h. A high parasite clearance rate was detected in 19 patients,
with PCTs from6 to 36 h, and 27 patients had a lowparasite clearance rate,
with PCTs between 90 and 132 h. In vitro drug susceptibility and PCT
phenotype data and Pfmrp2 genotype associations were tested by using a
one-way analysis of variance (ANOVA) with SPSS statistics software.
Topology of the PfMRP2 protein. To predict the transmembranes
(TM) in the ABC transporter PfMRP2, we used two different software
programs. The most-used program was TMHMM server v. 2.0 (trans-
Membrane hidden Markov model; http://www.cbs.dtu.dk/services
/TMHMM/). The other program used was the OCTOPUS software (29),
which uses a combination of hidden Markov models and artificial neural
networks. The topology predictor program OCTOPUS, in particular, is
the first to integrate modeling of reentrant, membrane dip, and TM hair-
pin regions in the topological grammar. It performs a homology search by
using BLAST to create a sequence profile used as the input to a set of
neural networks that predict both the preference for each residue to be
located in a TM, interface, close loop, or globular loop environment and
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to be inside or outside themembrane. These predictions are used as input
for a two-track hidden Markov model, which uses them to calculate the
most likely topology. To get a reliable model, we merged the data of the
two transmembrane predictive software programs. Table 1 and Fig. S1 in
the supplemental material show the membrane-spanning domains and
trans-membrane prediction of PfMRP2, and Fig. 1 shows a PfMRP2 two-
dimensional (2D) representation with the localization of the analyzed
SNPs and microindels.
Statistical analysis.To evaluate associations between the genetic poly-
morphisms found in Pfmrp2 and in vitro drug resistance, a one-way
ANOVA was performed to compare the mean IC50s of ART, DHA, MQ,
LUM, PPQ, and CQ. This analysis was complemented with chi-square
analysis to verify the presence of differences in the parasite clearance rates
that were high (36 h) and low (90 h). The SPSS package (IBM SPSS
Statistics v. 19)was used to conduct all statistical analyses, and results were
considered significant when P was0.05.
Nucleotide sequence accession numbers. The Pfmrp2 consensus se-
quences from the 46Thai parasites were submitted toGenBank (accession
numbers KM213123 to KM213168).
RESULTS
Analysis of the primary sequence organization of PfMRP2. The
predicted two-dimensional structure of PfMRP2 suggested a clas-
sical ABC transporter protein, with 12TMdomains, distributed in
two membrane-spanning domains (MSDs), and two nucleotide-
binding domains (NBDs). The data support previously proposed
models (13) of PfMRP2 as a transporter with 2 MSDs of 6 units
each (prediction probability range, 0.9 to 1). However, according
TABLE 1 Membrane-spanning domains and transmembrane
predictions for PfMRP2
MSD TM
Predicted TM domaina (aa span) based on:
Previously
published
(13) OCTOPUS TMHMM
O/T
merged
MSD1 1 133–155 133–157 132–155 134–155
2 180–202 178–199 180–203 180–199
3 402–424 401–422 396–418 401–418
4 434–456 425–449 428–454 428–448
5 517–539 511–531 511–533 512–531
6 554–575 544–564 548–565 551–562
— 787–807 — —
MSD2 7 — 1397–1419 1398–1426 1400–1417
8 1430–1452 1445–1472 1446–1471 1448–1470
1473–1495 — 1485–1506 —
9 1510–1532 1524–1545 1526–1546 1528–1545
10 1553–1570 1547–1564 1547–1565 1547–1564
11 1574–1593 1629–1658 1629–1651 1631–1651
12 1654–1676 1667–1689 1671–1693 1671–1689
a The TM segments shown are those reported from a previous study (13) or predicted
in this study by using the OCTOPUS and TMHMM software. To obtain a reliable
model, we supported the information for the TM segments obtained by merging the
OCTOPUS/TMHMM probabilities (i.e., data in the O/T merged column). TM domain
amino acid ranges shown in bold had the greatest differences from the data obtained
from reference 13 or via analysis using the OCTOPUS and TMHMM software
programs. TM column represents the transmembrane number for the O/T merged
model. Dashes (—) represent TM segments.
FIG 1 2D representation of PfMRP2, with the location of the analyzed SNPs and microindels. The structure depicted refers to the reference P. falciparum 3D7
clone sequence, comprising 2,108 aa. Note that the numbering of amino acids follows the 3D7 reference genomic data, independently of themicroindel variation
observed in the studied Thai set of parasites.
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to our analysis, we detected some differences in TM7 and TM11
predictions when we used the merged data from TMHMM and
OCTOPUS (Table 1; see also Fig. S1 in the supplemental mate-
rial). In our work, we identified TM7 between amino acids (aa)
1400 and 1417 which were not detected in previous analysis (13),
while T11 was repositioned. These observed divergences did not
interfere with the analysis or interpretation of our data, since none
of the subsequently identified SNPs were located in these regions.
In spite of its large size, PfMRP2 is predicted to represent a
short MRP-type protein, as it did not show the extra 5 TM
N-terminal domains present in the long MRPs, such as the
human MRPs 1, 2, 3, 6, and 7. This was largely compensated by
a large (850-aa) NBD1-containing cytoplasmic loop. Also
notable was the unusually distal localization of the NBD2 ABC
signature plus Walker B motif, which was only 17 aa from the
protein C-terminal.
Pfmrp2 polymorphisms. The Pfmrp2ORF was sequenced for
46 P. falciparum strains that originated from the Thai-Burma bor-
der. The full sequence was determined for 37/46 isolates, and on
average 93% of the gene was covered for the remaining 9 isolates.
A total of 12 nonsynonymous and 6 synonymous SNPs were iden-
tified, in comparison with the 3D7 reference sequence. Among
these SNPs, we found novel SNPs not previously annotatedwithin
PlasmoDB (http://plasmodb.org) nor observed in recently per-
formed genome surveys (30) or in other available genome se-
quencing data (31) (Table 2). The proportions of the analyzed
SNPs in this set of isolates varied from a single event (1/46) to
situations of monomorphism (46/46).
The only three nonsynonymous SNPs located in the predicted
TM domains of the transporter, L199V (TM2), S1527T (TM9),
and L1531I (TM9), were found to be monomorphic among the
studied isolates, suggesting that inheritance was from a common
ancestor (Table 2).
We also found a significant number of MIs, based on the pres-
ence of tandem repeats (Fig. 1 and 2), relative to the 3D7 reference
sequence. This is an unusual observation among P. falciparum
ABC transporters. The identified MIs comprise 5 regions of the
gene (herein referred asMI-I toMI-V) and lead to a notable length
variation of the coded protein (2,109 to 2,135 aa). Within the MI
regions, we also found variations in single nucleotides, troubling a
forthright sequence alignment. Three of these variations (D976N,
D1180N, and D1188N) are annotated as SNPs within PlasmoDB.
Due to the changeability of possible alignments, allocating an
amino acid position becomes biased, and thereforewe decided not
to include them as definitive SNPs but instead as residues of vari-
ability within the MIs (Fig. 2).
To additionally support the observation of such complex
Pfmrp2 MI regions, publicly available sequence data from 5 dis-
tinct parasite lines (Dd2, Hb3, UGT5.1, RAJ116, and IGH-CR14)
were aligned with the set of Thai isolates under study. The result-
ing analysis confirmed the presence of the 5 MIs determined in
our set of samples, further increasing the number of variants in
each MI region (Fig. 2). All MI regions were located outside the
TM domains.
Genotype/phenotype associations. The isolates under study
were previously shown to have a relatively large range of IC values
for the tested antimalarial drugs, withmedian IC50s (maximum to
minimum) of 7.4 nM (1.2 to 19.5 nM) for ART, 1.2 nM (0.3 to 5.3
nM) for DHA, 92.5 nM (16.5 to 270.8 nM) for MQ, 11.9 nM (2.0
to 40.8 nM) for LUM, and 39.4 nM (13.8 to 108.2 nM) for PPQ; all
strains were highly resistant to CQ, with IC50s of450 nM (454 to
1,027 nM) (21, 22).
One-way analysis of variance revealed an association between
the synonymous SNP coding for an asparagine at position 1138
(codon change of GAT¡ GAC at nucleotide position 3414) and
the parasite response to CQ (P 0.040), with an average IC50 for
the t3414 variant of 660 nM and for the c3414 variant of 564.3 nM
(Fig. 3). No other significant association was found within the
identified SNPs.
The 5MIs identified were subcategorized intoMI variants that
were type a, such as the 3D7 reference genomic sequence (Fig. 2).
With this classification approach, associative trends were revealed
TABLE 2 SNPs identified in Pfmrp2 by sequencing the Thai isolates
Chromosome
positiona
Nucleotide
position
Nucleotide
change
Amino acid
position
Amino acid
change
Frequency
(proportion) Location
1198644 561 T¡ A 187 Synonymous 0.02 (1/46) TM2
1198610*# 595 C¡ G 199 L¡ V 1.00 (46/46) TM2
1198321 884 C¡ G 295 T¡ R 0.02 (1/46) loop
1198275 930 G¡ T 310 L¡ F 0.02 (1/46) loop
1198224 981 C¡ T 327 Synonymous 0.02 (1/46) loop
1197428*§ 1777 A¡ G 593 N¡ D 0.07 (3/46) NBD1
1197341* 1864 A¡ G 622 N¡ D 0.22 (10/46) NBD1
1197064*§# 2141 A¡ T 714 K¡ I 1.00 (46/46) NBD1
1196808*§ 2397 C¡ T 799 Synonymous 0.39 (16/41) NBD1
1195791*§ 3414 T¡ C 1138 Synonymous 0.20 (9/44) NBD1
1194626*# 4579 T¡ A 1527 S¡ T 1.00 (46/46) TM9
1194614*# 4591 C¡ A 1531 L¡ I 1.00 (46/46) TM9
1194093 5112 T¡ C 1704 Synonymous 0.02 (1/46) NBD2
1193954 5251 A¡ T 1751 N¡ Y 0.09 (3/34) NBD2
1193947§ 5258 T¡ C 1753 F¡ S 0.07 (3/46) NBD2
1193882 5323 A¡ G 1775 I¡ V 0.14 (5/36) NBD2
1193861 5344 A¡ T 1782 M¡ L 0.02 (1/46) NBD2
1193820 5385 A¡ T 1795 Synonymous 0.08 (3/37) NBD2
a Symbols: *, SNP previously registered with PlasmoDB; §, SNP previously found by deep sequencing of 227 samples from Africa, Asia, and Oceania (30); #, SNP previously
described in reference 31.
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FIG2 Microindels identified in the Pfmrp2 by sequencing the Thai isolates and aligning the sequences with publicly available sequencing data. The 5microindels
identified were subcategorized as MI variants of type a (the 3D7 reference genomic sequence type); the other types are designated b to l for the variants found
among the Thai isolates (N) and the publicly available genomes. Symbols for publicly available genomes: £, Dd2; &, Hb3; #, UGT5.1; §, RAJ116;, IGH-CR14.
Highlighted black boxes denote amino acid positions that are described in the PlasmoDB database (http://www.plasmodb.org) as single nucleotide
polymorphisms.
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for MI-II-g type and PPQ IC50s (P  0.028), with mean IC50 of
37.4 nM in the absence of the polymorphism and of 57.4 nM in
isolates containing this type of polymorphism. The MI-V-b type
showed a trend of association with MQ susceptibility (P 0.042)
that encompassed an increased number of asparagines (N) from
10 (mean IC50 of 113.6 nM) to 14 (mean IC50 of 34.9 nM) (Fig. 3).
Interestingly, we observed the PCT phenotype to be influenced
by MI polymorphisms. For MI-II, the presence of the type II-a
allele was significantly more frequent in those parasites with high
clearance rates (P 0.025) (Fig. 3).
DISCUSSION
The PfMRP2 ABC transporter has been found to be located in the
plasma membrane (13). Conceptually, its localization and pre-
dicted function suggest this ABC transporter is of potential rele-
vance in the efflux of xenobiotics from the parasite cytoplasm, as
reported for the structurally related PfMRP1 (14).
The present work shows that Pfmrp2 harbors frequent and
complex natural variations, including SNPs and MIs based on
tandem repeats. The accumulation of these polymorphisms gives
rise to a significant level of diversity in this protein,more extensive
than that documented for any of the two previously well-investi-
gated ABC transporters in P. falciparum, Pgh-1 and PfMRP1. This
high diversity implies the existence of PfMRP2 natural variants
with different sizes and possible conformations and consequent
varied transporting capacities.
Compared with the first characterization of this gene by Mu et
al., in which 97 isolates from geographically distinct regions were
analyzed, our investigations revealed a notably higher frequency
of SNP/kb (2.8 versus 1.3 SNP/kb) (33). Of note, since the main
goal of our work was to understand the influence of the Pfmrp2
gene in drug susceptibility and parasite clearance, the set of para-
sites used in our study was expected to represent a relatively ho-
mogeneous sample. As such, and as in most other similar types of
studies, the observed polymorphism frequencies should not be
taken as representative of Southeast Asian P. falciparum popula-
tions as a whole. On the other hand, we expect most of the ob-
served polymorphisms to be relatively common (i.e., 1% fre-
quency) in the targeted region. Also such a low prevalence can
rapidly increase in time upon drug pressure. Such events can be
relevant in the context of this work, due to the notorious tendency
for Southeast Asia parasite populations to develop resistance.
Our data are suggestive of an involvement of this gene inmod-
ulating parasite drug sensitivity to at least some of the drugs tested.
In the particular case of CQ, and acknowledging that all the ana-
lyzed Thai isolates carry the pfcrt 76T allele (21), we observed an
association between the parasite sensitivity and a synonymous
SNP coding for an asparagine at aa 1138 (GAT¡GAC). Explain-
ing the effect of a synonymous mutation in a phenotype has been
a challenge in other areas of drug transport proteins. The presently
most favored hypothesis is based on preferential codon usage. In
P. falciparum, the two possible triplets that code for the asparagine
amino acid have very distinct frequencies. Codon usage analysis
describes the triplet GAU appearing at a greater frequency (55%)
than the triplet GAC (only 9%) (34). The use of alternative codons
with different levels of intracellular availability in terms of loaded
tRNA molecules is thought to influence translation rates. This
hypothesis has been experimentally put forward through investi-
gations of the synonymous t3434c SNP in the human P-glycopro-
tein, which is known to influence the exposure of some orally
administered drugs (35). Indeed, it has been demonstrated that
the nucleotide change disturbs the pace of the mRNA translation
FIG 3 SNPs and microindels and their associations with IC50 values and parasite clearance rates. We used one-way ANOVA to compare associations between
IC50s and the presence () or absence () of the SNP or microindel type. Chi-square analysis was used to compare associations between high (36-h) or low
(90-h) parasite clearance rates and the presence () or absence () of the SNP ormicroindel type. *, P 0.05 (significant findings are also highlighted in gray,
for additional emphasis. #, the number of samples bearing each genotype. Results represent only the analysis for genotypes with allele frequencies of8%.
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process, leading to changes in the conformational dynamics of the
nascent protein toward its final three-dimensional shape (36, 37).
Such a mechanistic hypothesis is worthy of investigation in the
context of P. falciparum biology.
As documented for other ABC transporters in P. falciparum
(32), PfMRP2 has divergent insertions throughout its protein se-
quence, which normally occur within protein domain linkers. Al-
though already observed in other P. falciparum ABC transporters,
namely, Pgh-1, the number and extension of polymorphisms of
these structures in PfMRP2 are unprecedented (Fig. 1 and 2). All
MI regions found are localized outside the TM domains. Their
exclusion from such protein regions is probably related to the
inability of the transmembrane domains to accommodate this
type of polymorphism, as the polymorphisms most likely alter
the intramembrane 	-helix structure, leading to functionally
deleterious distortions in the three-dimensional structure of
the protein. Considering their location, the extension of these
polymorphisms is expected to have a nonnegligible effect in the
protein structure and potentially in its function. Unfortunately, in
contrast with our previous work on the ABC transporter Pgh-1
(32), the large number of variable insertions/deletions impaired
the development of a meaningful homology structure model to
validate its impact on the protein’s function.
Suggestively, associative trends were revealed between varia-
tions in the MI-II region and the IC50s of PPQ, a 4-aminoquino-
line structurally related to CQ. These data are consistent with the
fact that CQ and PPQ show a degree of cross-resistance (22). An
increase of asparagines from 10 to 14 at the MI-V region was also
found associated with increased MQ susceptibility. It is conceiv-
able that these variations alter the steady-state conformations of
the cytoplasmic regions of the protein and with that, the interac-
tion with the antimalarial drugs, affecting their efflux out of the
parasite. The proposed potential role of PfMRP2 in the drug re-
sponse to CQ and MQ is further supported by the recent DNA
microarray-based observations that associated Pfmrp2 promoter
polymorphisms with the parasite CQ and MQ responses in vitro
(20).
Recently, Okombo et al. (38) found associations between vari-
ation in the size of the PfMRP2 MI-III and the in vitro parasite
responses to lumefantrine. Since this MI region was not polymor-
phic in our analyzed set of isolates (all have the DNNNTS se-
quence deleted), our study does not confirm or deny the previ-
ously reported observation. It is possible that this might be related
to the fact that, although the present study includes a substantial
number of laboratory-adapted strains, the herein-revealed biodi-
versity of this gene will demand future studies with larger sample
sizes for definitive determination of the role of PfMRP2 in the
parasite response to antimalarial drugs.
We are reporting for the first time a likely influence of the
variable MI regions on the parasite clearance time upon ACT
treatment (artesunate-mefloquine). Although these data are pre-
liminary, they suggest a potential role of PfMRP2 in the capacity
for the parasite to withstand clinical levels of artemisinin (and
possibly mefloquine). It is possible that some of these variants
involve fitness costs that become evident upon exposure to a stres-
sor, like the aforementioned drugs. Though a change in fitness
characteristics by itself may not be considered a resistance re-
sponse (39), our data point to the potential contribution of
PfMRP2 in the capacity of the parasite in evading the action of
these powerful but short-term drugs.
The likely influence of PfMRP2 on the parasite response to
multiple drugsmirrors that reported for PfMRP1 and its proposed
role in CQ, artemisinin, quinine, mefloquine, and lumefantrine
(14, 16, 40, 41). The present report adds to several independent
lines of evidence by our investigators and others, suggesting the
importance of MRP-like proteins in parasite drug responses,
highlighting the genetic variances found herein with their poten-
tial use as molecular sentinel tools.
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